These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27697838)

  • 21. On sample size estimation and re-estimation adjusting for variability in confirmatory trials.
    Wu PS; Lin M; Chow SC
    J Biopharm Stat; 2016; 26(1):44-54. PubMed ID: 26378970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interim analysis and sample size reassessment.
    Posch M; Bauer P
    Biometrics; 2000 Dec; 56(4):1170-6. PubMed ID: 11129475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blinded assessment of treatment effects for survival endpoint in an ongoing trial.
    Xie J; Quan H; Zhang J
    Pharm Stat; 2012; 11(3):204-13. PubMed ID: 22337644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Power Derivative Principle, and Its Application to How and When to Perform a One-Shot Unblinded Reassessment Sample Size.
    Blondiaux E; Derobert E
    Ther Innov Regul Sci; 2020 Jan; 54(1):117-127. PubMed ID: 32008247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
    Harden M; Friede T
    Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive statistical analysis following sample size modification based on interim review of effect size.
    Hung HM; Cui L; Wang SJ; Lawrence J
    J Biopharm Stat; 2005; 15(4):693-706. PubMed ID: 16022173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blinded sample size recalculation in clinical trials incorporating historical data.
    Hees K; Kieser M
    Contemp Clin Trials; 2017 Dec; 63():2-7. PubMed ID: 28735110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robustness of methods for blinded sample size re-estimation with overdispersed count data.
    Schneider S; Schmidli H; Friede T
    Stat Med; 2013 Sep; 32(21):3623-35. PubMed ID: 23595966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.
    Friede T; Schmidli H
    Stat Med; 2010 May; 29(10):1145-56. PubMed ID: 20146203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blinded sample size reassessment in non-inferiority and equivalence trials.
    Friede T; Kieser M
    Stat Med; 2003 Mar; 22(6):995-1007. PubMed ID: 12627414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design for sample size re-estimation with interim data for double-blind clinical trials with binary outcomes.
    Shih WJ; Zhao PL
    Stat Med; 1997 Sep; 16(17):1913-23. PubMed ID: 9304763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blinded sample size re-estimation for recurrent event data with time trends.
    Schneider S; Schmidli H; Friede T
    Stat Med; 2013 Dec; 32(30):5448-57. PubMed ID: 24105855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A SAS macro for sample size re-estimation.
    Zellner D; Zellner GE; Keller F
    Comput Methods Programs Biomed; 2001 Jun; 65(3):183-90. PubMed ID: 11339980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Point and interval estimation of primary and secondary parameters in a two-stage adaptive clinical trial.
    Liu A; Wu C; Yu KF
    J Biopharm Stat; 2008; 18(2):211-26. PubMed ID: 18327717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive blinded sample size adjustment for comparing two normal means--a mostly Bayesian approach.
    Hartley AM
    Pharm Stat; 2012; 11(3):230-40. PubMed ID: 22422722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation.
    Friede T; Kieser M
    Stat Med; 2002 Jan; 21(2):165-76. PubMed ID: 11782057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of the Gould-Shih procedure for sample size re-estimation.
    Waksman JA
    Pharm Stat; 2007; 6(1):53-65. PubMed ID: 17133631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.